First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity

Transurethral resection of the tumor (TUR-B) followed by adjuvant intravesical treatment with cytostatic drugs or Bacillus Calmette–Guérin (BCG) as standard therapy of non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence rate of about 60–70%, considerable side effects and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruf, Peter, Bauer, Hartwig W., Schoberth, Alexandra, Kellermann, Claudia, Lindhofer, Horst
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360869/
https://www.ncbi.nlm.nih.gov/pubmed/33837852
http://dx.doi.org/10.1007/s00262-021-02930-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360869/
https://www.ncbi.nlm.nih.gov/pubmed/33837852
http://dx.doi.org/10.1007/s00262-021-02930-7

Ejemplares similares